The RT-qPCR results of zebrafish verified that Pitavastatin inhibited the expression of HMGCR, while Cabazitaxel inhibited the expression of TUBB1. Our study suggested that Pitavastatin has therapeutic effects on OA, while Cabazitaxel increases the risk of OA.

10 days ago

Journal

CXCL8 (Chemokine (C-X-C motif) ligand 8) • BIRC3 (Baculoviral IAP repeat containing 3) • CCL20 (C-C Motif Chemokine Ligand 20) • ICAM1 (Intercellular adhesion molecule 1) • TUBB1 (Tubulin Beta 1 Class VI) • MMP3 (Matrix metallopeptidase 3)

cabazitaxel • pitavastatin

12d

Pitavastatin counteracts venetoclax resistance mechanisms in acute myeloid leukemia by depleting geranylgeranyl pyrophosphate. (PubMed, bioRxiv)

Loss of p53 function is strongly associated with venetoclax resistance, and adding venetoclax to 5-azacitidine provides no overall survival benefit in TP53 -mutant AML. The pro-apoptotic actions of pitavastatin depend on depletion of geranylgeranyl pyrophosphate (GGPP) and can be recapitulated by inhibiting GGPP synthase or geranylgeranyltransferase-1 enzymes. These results provide a mechanistic rationale for adding pitavastatin to AML regimens to prevent or overcome venetoclax resistance.

12 days ago

Journal • IO biomarker

TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • MCL1 (Myeloid cell leukemia 1)

TP53 mutation • FLT3 mutation

Venclexta (venetoclax) • azacitidine • pitavastatin

26d

Consensus Virtual Screening and Ex Vivo Evaluation of Novel JAK2/STAT1,3 Inhibitors. (PubMed, ACS Omega)

In the ex vivo evaluations, pitavastatin (0.5004 μM), eltrombopag (0.2548 μM), flavoxate (0.1536 μM), and empagliflozin (0.2548 μM) affected the phosphorylation of downstream STAT1 and STAT3 signaling molecules, similarly to tofacitinib citrate (TOF) (1.2 nM ). These results encourage further in-depth preclinical experiments aimed at exploring the additional effects of the JAK2-STAT1/3 signaling pathway.

26 days ago

Preclinical • Journal

JAK2 (Janus kinase 2) • IL6 (Interleukin 6) • STAT1 (Signal Transducer And Activator Of Transcription 1)

Promacta (eltrombopag) • tofacitinib • pitavastatin

Pitavastatin is a novel Mcl-1 inhibitor that overcomes paclitaxel resistance in triple-negative breast cancer. (PubMed, Exp Hematol Oncol)

PITA's inhibition of Mcl-1 represents a novel mechanism to address treatment-refractory metastatic TNBC. Further assessment of PITA's therapeutic potential is warranted.

1 month ago

Journal

BCL2 (B-cell CLL/lymphoma 2) • ALDH1A1 (Aldehyde Dehydrogenase 1 Family Member A1)

paclitaxel • pitavastatin

2ms

Elucidating the Inhibitory Potential of Statins Against Oncogenic c-Met Tyrosine Kinase Through Computational and Cell-based Studies. (PubMed, Iran J Pharm Res)

Machine learning led the experiment to find fluvastatin and pitavastatin as the two compounds with the highest inhibitory effects. However, no significant reduction in c-Met phosphorylation was observed by western blot. No relation between the statins' inhibitory effect and the c-Met pathway on cancerous cells could be reported.

2 months ago

Journal

MET (MET proto-oncogene, receptor tyrosine kinase) • HGF (Hepatocyte growth factor)

MET overexpression

pitavastatin

2ms

A Research Study of the Effect of Etavopivat on Other Drugs in Healthy Participants (clinicaltrials.gov)

P1, N=37, Completed, Novo Nordisk A/S | Recruiting --> Completed

2 months ago

Trial completion

metformin • midazolam hydrochloride • pitavastatin

3ms

A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib (clinicaltrials.gov)

P=N/A, N=8606, Recruiting, Boryung Pharmaceutical Co., Ltd | Trial completion date: Mar 2026 --> Jun 2026 | Trial primary completion date: Mar 2026 --> Jun 2026

3 months ago

Trial completion date • Trial primary completion date • Real-world evidence

pitavastatin

3ms

Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia (clinicaltrials.gov)

P1, N=6, Completed, University of California, Irvine | Active, not recruiting --> Completed | Trial completion date: Jun 2026 --> Feb 2025

3 months ago

Trial completion • Trial completion date

Venclexta (venetoclax) • azacitidine • pitavastatin

3ms

A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants (clinicaltrials.gov)

P1, N=40, Recruiting, Hoffmann-La Roche | Trial completion date: Dec 2025 --> May 2026 | Trial primary completion date: Dec 2025 --> May 2026

3 months ago

Trial completion date • Trial primary completion date

pitavastatin

4ms

A randomized, double-blind, placebo-controlled, dual-center clinical study to evaluate the efficacy and safety of pitavastatin calcium dispersible tablets in the treatment of active systemic lupus erythematosus (ChiCTR2400084812)

P=N/A, N=30, Recruiting, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College.; Hospital for Skin Disea | Not yet recruiting --> Recruiting

4 months ago

Enrollment open

pitavastatin

4ms

PIVOTAL: A Study to Evaluate the Effectiveness and Safety of Fixed-Dose Combination of Pitavastatin/ Ezetimibe (clinicaltrials.gov)

P=N/A, N=4500, Recruiting, Ahn-Gook Pharmaceuticals Co.,Ltd | Not yet recruiting --> Recruiting

4 months ago

Enrollment open

atorvastatin • pitavastatin

4ms

GUIDE-CAC: Statin-Ezetimibe Without Aspirin vs. Statin Monotherapy With Aspirin in High Coronary Calcification (clinicaltrials.gov)

P4, N=7435, Recruiting, Asan Medical Center | Not yet recruiting --> Recruiting

4 months ago

Enrollment open

pitavastatin